A 2022 investigation using a PheWAS approach in an earlier version of UKBB reported an excess risk (OR>3) for leukemia and plasma cell neoplasms in CHEK2 P/LP heterozygotes.28 To date with current approaches (e.g., CBC, physical exam) there is limited evidence-based actionability for surveillance for increased risk of leukemia, however with developing methods (e.g., methylation profiling of circulating tumor DNA) this may improve. This evidence concerns the gene CHEK2 and plasma cell neoplasm.